Assessing Patient Readiness for the Clinical Adoption of Personalized Medicine
Abstract
Background/Aims: Although pharmacogenomics-based diagnostics and therapeutics are increasingly being translated into personalized medicine applications, relatively little evidence exists about how novel pharmacogenomics-based technologies will be accepted and adopted by patients. It is important to understand the characteristics of genomic diagnostics and targeted therapeutics that might impact utilization or serve as barriers to adoption of these novel technologies in order to formulate appropriate policies and procedures. The objective of this study was to investigate patients’ understanding and knowledge of personalized medicine and the process of decision-making regarding pharmacogenomics testing and targeted therapeutics and to better understand how patients value receiving pharmacogenomics-based care. Methods: We conducted 4 focus groups with 8–10 individuals in each group with patients recruited from out-patient clinics at The Methodist Hospital in Houston, Tex., USA. Results: The use of genomic diagnostics and targeted therapeutics to facilitate personalized medicine has considerable support from patients. However, our data revealed that participants were concerned with issues surrounding privacy and confidentiality of genetic test results, particularly with respect to access of information by insurers, with potential costs of testing and issues related to accuracy of test results. Questions regarding willingness to pay revealed that patients would be more willing to pay out-of-pocket if the disease associated with pharmacogenomic testing for treatment was perceived to be high risk (e.g., colorectal cancer) versus a chronic condition that was perceived as lower risk (e.g., high cholesterol). Conclusion: As the personalized medicine approach is increasingly incorporated into health care, understanding patients’ needs and their readiness to adopt these novel technologies will become progressively more important for the development of appropriate health policies.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The willingness and interest to undergo precision medicine interventions and a positive attitude towards them is high among the majority of patients surveyed.
“The willingness and interest to undergo PM interventions and a positive attitude towards them is high among the majority of patients surveyed [29, 63, 65, 69, 73, 74, 77, 91–93].”
From Patients’ and professionals’ views related to ethical issues in precision medicine: a mixed research synthesis (2021) · cites this paper as [73]
Many patients generally have limited knowledge about precision medicine, genetic testing, and pharmacogenomics.
“However, as other studies have demonstrated, many patients generally have a limited knowledge about PM [65, 71, 99–102], genetic testing [62, 69, 95] and pharmacogenomics [73, 101] and also express difficulties in understanding [51].”
From Patients’ and professionals’ views related to ethical issues in precision medicine: a mixed research synthesis (2021) · cites this paper as [73]
Some patients also doubt the accuracy of the tests or the value of the test results to influence their fate.
“Some patients also doubt the accuracy of the tests [63, 73] or the value of the test results to influence their fate [61].”
From Patients’ and professionals’ views related to ethical issues in precision medicine: a mixed research synthesis (2021) · cites this paper as [73]
The willingness of patients to pay for PM themselves is apparently higher when the purpose is to treat a serious illness, such as cancer.
“The willingness of patients to pay for PM themselves is apparently higher when the purpose is to treat a serious illness, such as cancer [73].”
From Patients’ and professionals’ views related to ethical issues in precision medicine: a mixed research synthesis (2021) · cites this paper as [73]
Cites
Qualitative research and evaluation methods
Patton, M. Q. (1980) · Cited by 35,637 · see citing works
Vogel, C. L., Cobleigh, M., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.3.719 · Cited by 3,240 · see citing works
Mattley, C. L., Strauss, A., & Corbin, J. M. (1999) · Contemporary Sociology A Journal of Reviews · doi:10.2307/2655359 · Cited by 2,410 · see citing works
Basics of social research : qualitative and quantitative approaches
Neuman, W. L. (2003) · Cited by 1,411 · see citing works
Moving towards individualized medicine with pharmacogenomics
Evans, W. E., & Relling, M. V. (2004) · Nature · doi:10.1038/nature02626 · Cited by 772 · see citing works
The Price Tag on Progress — Chemotherapy for Colorectal Cancer
Schrag, D. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048143 · Cited by 437 · see citing works
Gafni, A. (1991) · PubMed · Cited by 190 · see citing works
Ethical perspectives on pharmacogenomic profiling in the drug development process
Issa, A. (2002) · Nature reviews. Drug discovery · doi:10.1038/nrd771 · Cited by 119 · see citing works
Self-citationEthical considerations in clinical pharmacogenomics research
Issa, A. M. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01493-0 · Cited by 81 · see citing works
Self-citationPharmacogenetics and the future of medical practice
Lindpaintner, K. (2003) · Journal of Molecular Medicine · doi:10.1007/s00109-002-0416-5 · Cited by 61 · see citing works
Zineh, I., Gerhard, T., Aquilante, C. L., Beitelshees, A. L., Beasley, B. N., & Hartzema, A. G. (2004) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500284 · Cited by 48 · see citing works
Liou, J., Ma, Y.-Y., Gibson, L. H., Su, H., Charest, N. J., Lau, Y. C., & Yang‐Feng, T. L. (1997) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19970516)70:2 · Cited by 47 · see citing works
A lay prescription for tailor-made drugs—focus group reflections on pharmacogenomics
Almarsdóttir, A. B., Björnsdóttir, I., & Traulsen, J. M. (2004) · Health Policy · doi:10.1016/j.healthpol.2004.08.010 · Cited by 40 · see citing works
Measuring women's preferences for breast cancer treatments and BRCA1/BRCA2 testing
Cappelli, M., Surh, L. C., Humphreys, L., Verma, S., Logan, D., Hunter, A. G. W., & Allanson, J. E. (2001) · Quality of Life Research · doi:10.1023/a:1013123915272 · Cited by 38 · see citing works
Cohen, M. H., Moses, M. L., & Pazdur, R. (2002) · The Oncologist · doi:10.1634/theoncologist.7-5-390 · Cited by 35 · see citing works
Pharmacogenomics: the future of drug therapy
Tsai, Y., & Hoyme, H. (2002) · Clinical Genetics · doi:10.1034/j.1399-0004.2002.620401.x · Cited by 35 · see citing works
Attitudes Toward Genetic Testing in Patients At Risk for HNPCC/FAP and the German Population
Berth, H., Balck, F. B., & Dinkel, A. (2002) · Genetic Testing · doi:10.1089/10906570260471804 · Cited by 33 · see citing works
Pharmacogenomics: out of the lab and into the community
Nebert, D. W. (2001) · Trends in biotechnology · doi:10.1016/s0167-7799(01)01805-4 · Cited by 32 · see citing works
Pharmacogenetics: the ethical context
Thomas, S. M. (2001) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500052 · Cited by 30 · see citing works
Dranitsaris, G. (1997) · Supportive Care in Cancer · doi:10.1007/s005200050118 · Cited by 29 · see citing works
Freudenberg-Hua, Y., Freudenberg, J., Winantea, J., Kluck, N., Cichon, S., Brüss, M., Propping, P., & Nöthen, M. M. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500306 · Cited by 14 · see citing works
Clinical applications of pharmacogenomics to adverse drug reactions
Issa, A. M. (2008) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.1.2.251 · Cited by 7 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Pulley, J. M., Denny, J. C., Peterson, J., Bernard, G. R., Vnencak-Jones, C. L., Ramirez, A. H., Delaney, J. T., Bowton, E., Brothers, K., Johnson, K. B., et al. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.371 · Cited by 414 · see citing works
Public Opinion about the Importance of Privacy in Biobank Research
Kaufman, D. J., Murphy-Bollinger, J., Scott, J., & Hudson, K. L. (2009) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2009.10.002 · Cited by 279 · see citing works
Miller, F. A., Hayeems, R. Z., Bytautas, J. P., Bedard, P. L., Ernst, S., Hirte, H., Hotte, S., Oza, A., Razak, A., Welch, S., et al. (2014) · European Journal of Human Genetics · doi:10.1038/ejhg.2013.158 · Cited by 116 · see citing works
Erdmann, A., Rehmann-Sutter, C., & Bozzaro, C. (2021) · BMC Medical Ethics · doi:10.1186/s12910-021-00682-8 · Cited by 86 · see citing works
The potential impact of pharmacogenetic testing on medication adherence
Haga, S. B., & LaPointe, N. M. A. (2013) · The Pharmacogenomics Journal · doi:10.1038/tpj.2013.33 · Cited by 77 · see citing works
Wu, A. C., Kiley, J. P., Noel, P. J., Amur, S., Burchard, E. G., Clancy, J. P., Galanter, J., Inada, M., Jones, T. K., Kropski, J. A., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201810-1895st · Cited by 68 · see citing works
Gordon, E. S., Griffin, G., Wawak, L., Pang, H., Gollust, S. E., & Bernhardt, B. A. (2011) · Journal of Genetic Counseling · doi:10.1007/s10897-011-9476-4 · Cited by 65 · see citing works
Stakeholder Views on Pharmacogenomic Testing
Patel, H., Ursan, I. D., Zueger, P., Cavallari, L. H., & Pickard, A. S. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1364 · Cited by 50 · see citing works
Assessment of patient perceptions of genomic testing to inform pharmacogenomic implementation
Lee, Y. M., McKillip, R. P., Borden, B. A., Klammer, C., Ratain, M. J., & O’Donnell, P. H. (2017) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000275 · Cited by 49 · see citing works
Cancer patients’ acceptance, understanding, and willingness-to-pay for pharmacogenomic testing
Cuffe, S. D., Hon, H., Qiu, X., Tobros, K., Wong, C.-K. A., Souza, B. D., McFarlane, G., Masroor, S., Azad, A. K., Hasani, E., et al. (2014) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000061 · Cited by 38 · see citing works
Self-citationRacial Differences in Attitudes toward Personalized Medicine
Diaz, V. A., Mainous III, A. G., Gavin, J. K., & Wilson, D. (2014) · Public Health Genomics · doi:10.1159/000354785 · Cited by 36 · see citing works
PELLEGRINI, I., Rapti, M., Extra, J.-M., Petri-Cal, A., Apostolidis, T., Ferrero, J.-M., Bachelot, T., Viens, P., Julian‐Reynier, C., & Bertucci, F. (2011) · European Journal of Cancer Care · doi:10.1111/j.1365-2354.2011.01300.x · Cited by 34 · see citing works
Personalized Genomic Results: Analysis of Informational Needs
Schmidlen, T., Wawak, L., Kasper, R. S., García‐España, J. F., Christman, M. F., & Gordon, E. S. (2014) · Journal of Genetic Counseling · doi:10.1007/s10897-014-9693-8 · Cited by 32 · see citing works
Najafzadeh, M., Johnston, K., Peacock, S. J., Connors, J. M., Marra, M. A., Lynd, L. D., & Marra, C. A. (2013) · BMC Health Services Research · doi:10.1186/1472-6963-13-454 · Cited by 32 · see citing works
McKillip, R. P., Borden, B., Gałecki, P., Ham, S. A., Patrick‐Miller, L. J., Hall, J. P., Hussain, S., Danahey, K., Siegler, M. A., Sorrentino, M. J., et al. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.586 · Cited by 32 · see citing works
Qureshi, S., Latif, A., Condon, L. A., Akyea, R. K., Kai, J., & Qureshi, N. (2021) · Pharmacogenomics · doi:10.2217/pgs-2021-0131 · Cited by 31 · see citing works
Facilitators and Barriers to the Adoption of Pharmacogenetic Testing in an Inner‐City Population
Lee, Y. M., Manzoor, B. S., Cavallari, L. H., & Nutescu, E. A. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2077 · Cited by 29 · see citing works
Public Perceptions of Pharmacogenetics
Zhang, S. C., Carleton, B., Hayden, M. R., & Rieder, M. J. (2014) · PEDIATRICS · doi:10.1542/peds.2013-1416 · Cited by 28 · see citing works
Lu, C. Y., Williams, M. S., Ginsburg, G. S., Toh, S., Brown, J. S., & Khoury, M. J. (2017) · Genetics in Medicine · doi:10.1038/gim.2017.122 · Cited by 27 · see citing works
Liang, R., Meiser, B., Smith, S. K., Kasparian, N. A., Lewis, C. R., Chin, M. T. M., Long, G. V., Ward, R. L., Menzies, A. M., Harris-Wai, J. N., et al. (2016) · European Journal of Cancer Care · doi:10.1111/ecc.12600 · Cited by 26 · see citing works
Patient reactions to personalized medicine vignettes: An experimental design
Butrick, M., ROTER, D. L., Kaphingst, K. A., Erby, L. H., Haywood, C., Beach, M. C., & Levy, H. P. (2011) · Genetics in Medicine · doi:10.1097/gim.0b013e3182056133 · Cited by 23 · see citing works
Holden, C., Bignell, L., Mukhopadhyay, S., & Jones, C. J. (2019) · Personalized Medicine · doi:10.2217/pme-2018-0151 · Cited by 20 · see citing works
Pereira, N. L., So, D. Y. F., Bae, J., Chavez, I. J., Jeong, M. H., Kim, S., Madan, M., Graham, J. J., O’Cochlain, F., Pauley, N., et al. (2019) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000368 · Cited by 17 · see citing works
Issa, A. M., Tufail, W., Atehortua, N., & McKeever, J. (2013) · Personalized Medicine · doi:10.2217/pme.13.17 · Cited by 16 · see citing works
Self-citationLachance, K., Korol, S., O’Meara, E., Ducharme, A., Racine, N., Liszkowski, M., Rouleau, J. L., Pelletier, G. B., Carrier, M., White, M., et al. (2014) · The Pharmacogenomics Journal · doi:10.1038/tpj.2014.29 · Cited by 15 · see citing works
Individual differences in human opioid abuse potential as observed in a human laboratory study
Dunn, K. E., Barrett, F. S., Brands, B., Marsh, D. C., & Bigelow, G. E. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.107688 · Cited by 15 · see citing works
Value of Genetic Testing for Hereditary Colorectal Cancer in a Probability-Based US Online Sample
Knight, S. J., Mohamed, A. F., Marshall, D. A., Ladabaum, U., Phillips, K. A., & Walsh, J. M. E. (2015) · Medical Decision Making · doi:10.1177/0272989x14565820 · Cited by 14 · see citing works
Deininger, K. M., Tran, J. N., Tsunoda, S. M., Young, G. K., Lee, Y. M., Anderson, H. D., Page, R. L., II, Hirsch, J. D., & Aquilante, C. L. (2019) · Pharmacogenomics · doi:10.2217/pgs-2019-0129 · Cited by 14 · see citing works
Issa, A. M., Hutchinson, J. F., Tufail, W., Fletcher, E. H., Ajike, R., & Tenorio, J. (2011) · Personalized Medicine · doi:10.2217/pme.11.39 · Cited by 13 · see citing works
Self-citationArar, N. H., Knight, S. J., Modell, S. M., & Issa, A. M. (2011) · Personalized Medicine · doi:10.2217/pme.11.5 · Cited by 11 · see citing works
Self-citationSeror, V., Marino, P., Bertucci, F., Mancini, J., Extra, J.-M., Ferrero, J.-M., Bachelot, T., Viens, P., & Julian‐Reynier, C. (2013) · Public Health Genomics · doi:10.1159/000349920 · Cited by 9 · see citing works
Henrich, N. J., Holmes, B. J., & Prystajecky, N. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141533 · Cited by 8 · see citing works
Role of Pharmacogenomics in Comprehensive Medication Management: Considerations for Employers
Fragala, M. S., Shaman, J. A., Lorenz, R. A., & Goldberg, S. E. (2022) · Population Health Management · doi:10.1089/pop.2022.0075 · Cited by 7 · see citing works
Martin, P., Brown, M. C., Espin‐Garcia, O., Cuffe, S. D., Pringle, D., Mahler, M. B., Flamand-Villeneuve, J., Niu, C., Charow, R., Lam, C., et al. (2015) · European Journal of Cancer Care · doi:10.1111/ecc.12318 · Cited by 7 · see citing works
Chapdelaine, A., Lamoureux‐Lamarche, C., Poder, T. G., & Vasiliadis, H. (2021) · Pharmacogenomics · doi:10.2217/pgs-2020-0077 · Cited by 7 · see citing works
Preferences for pharmacogenomic testing in polypharmacy patients: a discrete choice experiment
Chen, C., Roberts, M. H., Raisch, D. W., Thompson, T. A., Bachyrycz, A. M., & Borrego, M. E. (2022) · Personalized Medicine · doi:10.2217/pme-2022-0056 · Cited by 6 · see citing works
Behavioral Oncology and the War on Cancer: Partnering with Biomedicine
Stefanek, M. E., Andrykowski, M. A., Lerman, C. E., Manne, S. L., Glanz, K., & on behalf of the AACR Behavioral Science Task Force (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4005 · Cited by 6 · see citing works
Leppin, A., & Nielsen, J. B. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12111836 · Cited by 5 · see citing works
Bashir, N. S., & Ungar, W. J. (2015) · Genome · doi:10.1139/gen-2015-0100 · Cited by 5 · see citing works
Debnath, M., Prasad, G. B. K. S., & Bisen, P. S. (2009) · Springer eBooks · doi:10.1007/978-90-481-3261-4_23 · Cited by 5 · see citing works
Precision Medicine in Primary Health Care
Bartlett, G., Dawes, M. G., Nguyen, Q. N., & Phillips, M. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809411-2.00005-2 · Cited by 4 · see citing works
Clasen, K., Gani, C., Schroeder, C., Rieß, O., Zips, D., Schöffski, O., & Clasen, S. (2022) · Personalized Medicine · doi:10.2217/pme-2021-0067 · Cited by 4 · see citing works
ATTITUDES ON WARFARIN PHARMACOGENETIC TESTING IN CHINESE PATIENTS AND PUBLIC
Chan, S. L., Low, J. J. W., Chia, K. S., & Wee, H. L. (2014) · International Journal of Technology Assessment in Health Care · doi:10.1017/s026646231300069x · Cited by 4 · see citing works
Moriarty, K. E., Wolf, S. M., Veach, P. M., LeRoy, B. S., MacFarlane, I. M., & Zierhut, H. A. (2020) · Personalized Medicine · doi:10.2217/pme-2019-0125 · Cited by 2 · see citing works
A Novel Transformation Model© for Personalized Medicine Laboratory Systems
McKibben, L. J., Boone, D. J., Marchibroda, J. M., & Issa, A. M. (2009) · Personalized Medicine · doi:10.2217/pme.09.66 · Cited by 2 · see citing works
Self-citationEthical Considerations in the Genomic Era
Ellul, B. (2015) · Advances in predictive, preventive and personalised medicine · doi:10.1007/978-3-319-15344-5_13 · Cited by 2 · see citing works
Public preferences regarding adoption of personal genomic testing based on best–worst scaling
Jeong, G. (2018) · Health Policy and Technology · doi:10.1016/j.hlpt.2018.10.010 · Cited by 2 · see citing works
Kuderer, N. M., Burton, K. A., Blau, S. H., Senecal, F. M., Gadi, V. K., Parker, S., Mahen, E. M., Veenstra, D. L., Carlson, J. J., Lyman, G. H., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00076 · Cited by 2 · see citing works
Anantharajah, A., Chaudhry, R., Wittner, V. A., Cayabyab, M. A. S., Hoffecker, G., Wang, X., Conway, L. J., Biobank, P. M., Teitelbaum, U., & Tuteja, S. (2026) · Clinical and Translational Science · doi:10.1111/cts.70459 · Cited by 1 · see citing works
Integration of genomics into clinical care : methods for economic evaluation
Najafzadeh, M. (2012) · cIRcle (University of British Columbia) · doi:10.14288/1.0072612
Blackford Middleton, A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802115-6.00024-0
West, H. D., Formosa, N., Morgan, R., Vashista, T., Chauhan, P., Jegina, H., Muñoz, Á. N., McTavish, G., Campbell, S., John, W., et al. (2026) · Research for All · doi:10.14324/rfa.10.1.10
- Authors
- Issa, A. M., Tufail, W., Hutchinson, J., Tenorio, J., & Baliga, M. P.
- Affiliations
- Houston Methodist Research Institute (US)
- University of Houston (US)
- ORCID
- Issa, A.M.
- Venue
- Public Health Genomics
- Publisher
- S. Karger AG
- Published
- 2009
- Volume
- 12
- Issue
- 3
- Pages
- 163-169
- ISSN
- 1422-2795 (ISSN-L)
- 1662-4246
- 1662-8063
- OpenAlex
- W2076861819
- Cited by
- 52
- References
- 22
- Citations by year
- 2026: 2 · 2022: 4 · 2021: 3 · 2020: 1 · 2019: 4 · 2018: 2 · 2017: 5 · 2016: 3 · 2015: 5 · 2014: 5 · 2013: 7 · 2012: 2
- FWCI
- 3.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Public Health Genomics (publishedVersion)
- PubMed (publishedVersion)
- DigitalGeorgetown (Georgetown University Library) (submittedVersion)
- Funders
- Greenwall Foundation
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ethics in Clinical Research
- Health Sciences › Health Professions › General Health Professions › Patient-Provider Communication in Healthcare
- Keywords
- personalized medicine, pharmacogenomics, patient acceptance, genomic diagnostics, targeted therapeutics, willingness to pay, patient decision-making, patient knowledge, health policy
- MeSH terms
- Adult, Aged, Decision Making, Drug Therapy, Female, Humans, Male, Middle Aged, Patient Compliance, Personal Health Services, Pharmacogenetics, Molecular Diagnostic Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
